Status:
NO_LONGER_AVAILABLE
Use of Pan-vascular Endothelial Growth Factor Receptor (Pan-VEGF) Blockade for the Treatment of Retinopathy of Prematurity (ROP) (Compassionate Use BLOCK-ROP)
Lead Sponsor:
Children's Hospital Los Angeles
Conditions:
Retinopathy of Prematurity
Eligibility:
All Genders
30+ years
Brief Summary
The purpose of this study is to provide access to intravitreal injection of Avastin in high-risk infants who do not otherwise qualify for study NCT00702819, an investigational multi-site study examini...
Detailed Description
Retinopathy of Prematurity (ROP) is a leading cause of blindness in children in developed countries around the world, and an increasing cause of blindness in developing countries. The retina lines the...
Eligibility Criteria
Inclusion
- Inborn babies at CHLA NICU
- Outborn babies transferred to CHLA NICU
- Zone 1 or 2 ROP
- Adequate/appropriate laser ablation
- Failed standard laser treatment (persistent Plus disease at a minimum of 1 week post-laser)
- Post-menstrual age greater than 30 weeks
Exclusion
- Zone 3 ROP
- Inadequate initial laser treatment
- Most recent laser treatment less than 1 week
- Evidence of tractional retinal detachment (exudative retinal detachment may be included in study group)
- Post-menstrual age less than 30 weeks
- Health not allowing for full protocol participation (determined by neonatologist)
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00870636
Last Update
November 24 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Childrens Hospital Los Angeles
Los Angeles, California, United States, 90027